Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Wellington Shields & Co. LLC Acquires New Holdings in Insmed, Inc. $INSM
04:42am, Saturday, 07'th Feb 2026
Wellington Shields and Co. LLC bought a new stake in Insmed, Inc. (NASDAQ: INSM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commi
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
07:00am, Thursday, 05'th Feb 2026
BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Principal Financial Group Inc. Has $124.47 Million Holdings in Insmed, Inc. $INSM
05:18am, Tuesday, 03'rd Feb 2026
Principal Financial Group Inc. reduced its position in Insmed, Inc. (NASDAQ: INSM) by 35.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owne
Keybank National Association OH Has $2.41 Million Stock Holdings in Insmed, Inc. $INSM
04:40am, Tuesday, 03'rd Feb 2026
Keybank National Association OH grew its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 76.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch
08:15am, Monday, 02'nd Feb 2026
Insmed remains a compelling buy after an ~30% pullback, as Brinsupri's blockbuster launch trajectory outpaces initial expectations. Brinsupri delivered $144.6M in Q4 sales and 11,550 patient starts in
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
09:39am, Thursday, 29'th Jan 2026
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmo
Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Insmed, Inc. $INSM
05:48am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 36.9% during the undefined quarter, according to its most recent Form 13F filing with the S
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock
04:51am, Saturday, 24'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a tota
Artisan Small Cap Fund Q4 2025 Portfolio Activity
09:08am, Friday, 23'rd Jan 2026
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investme
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up a rollercoaster week marked by huge market swings. Still, ultimately, President Trump's TACO (Trump Always Chickens Out) mo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to c
Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares
04:48am, Wednesday, 14'th Jan 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 19,215 shares of the firm's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00,
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
04:27pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors ar
